Abivax shareholders vote on ATM share issuance plan, up to EUR 20,000 nominal

• Abivax shareholders will vote May 11, 2026 on a board authorization to issue ordinary shares under a US “at-the-market” (ATM) equity financing program.
• Measure would waive pre-emptive subscription rights for existing shareholders.
• Authorization would run 18 months, giving board discretion to set final issuance terms.
• Capital increase capacity would be capped at EUR 20,000 in nominal amount, subject to adjustments to protect holders of other securities.
• Statutory auditors raised no objection to pricing-setting methodology described by board, supporting adoption of resolution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.